Similar to the aforementioned lncRNAs, PCAT-18 can be detected in plasma, and its expression increases incrementally as prostate cancer progresses from localized to metastatic disease, suggesting that PCAT-18 is a potential biomarker for metastatic prostate cancer [38]. The gene discussed is PCAT18; the disease is metastatic neoplasm.